AtaCor Medical, a privately-held medical device company, has entered into a financing of up to $75 million. The proceeds will fund the company's U.S. FDA Pivotal Study evaluating AtaCor's parasternal extravascular implantable cardioverter-defibrillator (EV-ICD) system for the treatment of life-threatening ventricular tachyarrhythmias.
AtaCor's EV-ICD system consists of the Atala lead and an implantable pulse generator. The Atala lead is implanted via a small left parasternal incision, positioned through the rib space with electrodes placed against the pericardium, outside of the heart and vasculature. The pulse generator can be placed in either a lateral or pectoral subcutaneous device pocket, representing a novel option for EV-ICD systems. This unique EV-ICD system aims to deliver the benefits of defibrillation and antitachycardia pacing without the long-term risks associated with intravascular or intracardiac leads.
AtaCor recently completed enrollment of its ASCEND EV Pilot Study, with initial results accepted for presentation at the upcoming Asia Pacific Heart Rhythm Society (APHRS) meeting this November in Yokohama, Japan. Building on these initial results, AtaCor plans to launch the ALARION EV Pivotal Study in the United States and Europe in 2026, which aims to evaluate the safety and efficacy of the parasternal EV-ICD system and support global regulatory submissions.
The AtaCor EV-ICD Lead System is under development exclusively for investigational use and is not approved for sale in any geography.
